Cadrenal Therapeutics Inc. (CVKD): Price and Financial Metrics
CVKD Price/Volume Stats
| Current price | $0.43 | 52-week high | $3.14 |
| Prev. close | $0.41 | 52-week low | $0.36 |
| Day low | $0.40 | Volume | 108,300 |
| Day high | $0.44 | Avg. volume | 396,095 |
| 50-day MA | $0.61 | Dividend yield | N/A |
| 200-day MA | $0.73 | Market Cap | 6.83M |
CVKD Stock Price Chart Interactive Chart >
Latest CVKD News From Around the Web
Below are the latest news stories about CADRENAL THERAPEUTICS INC that investors may wish to consider to help them evaluate CVKD as an investment opportunity.
Noble Capital Markets Initiates Coverage on Cadrenal Therapeutics with Outperform Rating and US$4.00 Price TargetCadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes and deaths due to blood clots in patients with certain orphan diseases, today announced that Noble Capital Markets ("Noble") has initiated equity research coverage on the Company with an "Outperform" rating and a price target of US$4.00 per share. The full report by Noble Capital Markets Sen |
Cadrenal Therapeutics Engages The Sage Group to Advance Tecarfarin's Late-Stage Development and CommercializationCadrenal Therapeutics, Inc., (Nasdaq: CVKD) a biopharmaceutical company developing tecarfarin, a late-stage, novel, oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes and deaths (due to blood clots in patients with certain orphan diseases), today announced an engagement with The Sage Group (www.sagehealthcare.com) to assist the company in exploring strategic partnerships, co-development and licensing agreements for tecarfarin. |
Cadrenal Therapeutics to Present at the NobleCon 19 Conference on December 4, 2023Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes and deaths due to blood clots in patients with certain rare medical conditions, announced today that Quang Pham, CEO, will present at NobleCon19 - Noble Capital Markets' Nineteenth (19) Annual Emerging Growth Equity Conference at Florida Atlantic University, Executive Education Complex, in B |
Cadrenal Therapeutics Provides Third Quarter 2023 Corporate UpdateCadrenal Therapeutics, Inc., (Nasdaq: CVKD) ("Cadrenal Therapeutics" or the "Company") a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes and deaths due to blood clots in patients with certain rare medical conditions, today provided a corporate update in connection with the filing of its Quarterly Report on Form 10-Q for the quarter ended September 30, 2023. |
Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2023 Investor ConferenceCadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes and deaths due to blood clots in patients with certain rare medical conditions, announced today that Quang Pham, CEO, will be participating in a Company Webcast and Panel Presentation at the Lytham Partners Fall 2023 Investor Conference on Tuesday, October 17, 2023. Management will also be c |
CVKD Price Returns
| 1-mo | -31.75% |
| 3-mo | -66.92% |
| 6-mo | -8.04% |
| 1-year | -70.14% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -41.88% |
| 2023 | N/A |
| 2022 | N/A |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...